<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39373347</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>07</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1521-3773</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Oct</Month><Day>07</Day></PubDate></JournalIssue><Title>Angewandte Chemie (International ed. in English)</Title><ISOAbbreviation>Angew Chem Int Ed Engl</ISOAbbreviation></Journal><ArticleTitle>Synthesis of Low-Molecular-Weight Fucoidan Analogue and Its Inhibitory Activities against Heparanase and SARS-CoV-2 Infection.</ArticleTitle><Pagination><StartPage>e202411760</StartPage><MedlinePgn>e202411760</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/anie.202411760</ELocationID><Abstract><AbstractText>Heparan sulfate (HS) is ubiquitous on cell surfaces and is used as a receptor by many viruses including SARS-CoV-2. However, increased activity of the inflammatory enzyme heparanase (HPSE), which hydrolyses HS, in patients with COVID-19 not only increases the severity of symptoms but also may facilitate the spread of the virus by degrading HS on the cell surface. Therefore, synthetic HPSE blockades, which can bind to SARS-CoV-2 spike protein (SARS-CoV-2-S) and inhibit viral entry, have attracted much attention. This study investigated the development of a new dual-targeting antiviral agent against HPSE and SARS-CoV-2-S using fucoidan as a structural motif. It was found that all-sulfated fucoidan derivative 10, which exhibited the highest binding affinity to SARS-CoV-2-S among 13 derivatives, also showed the highest inhibitory activity against HPSE. Based on this, a newly designed and synthesized fucoidan analogue 16, in which the octyl group of 10 was changed to a cholestanyl group, was found to show higher activity than 10 but did not inhibit factor Xa associated with undesired anticoagulant effects. The binding affinity of 16 to SARS-CoV-2-S was significantly increased approximately 400-fold over that of 10. Furthermore, 16 effectively inhibited infection by the SARS-CoV-2 Wuhan strain and two Omicron subvariants.</AbstractText><CopyrightInformation>© 2024 Wiley‐VCH GmbH.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sugimoto</LastName><ForeName>Aoi</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Keio University Faculty of Science and Technology Graduate School of Science and Technology, Applied Chemistry, 3-14-1 Hiyoshi, Kohoku-ku, 223-8522, Yokohama, JAPAN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koike</LastName><ForeName>Tatsuki</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Keio University Faculty of Science and Technology Graduate School of Science and Technology, Applied Chemistry, 3-14-1 Hiyoshi, Kohoku-ku, 223-8522, Yokohama, JAPAN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kuboki</LastName><ForeName>Yuya</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Keio University Faculty of Science and Technology Graduate School of Science and Technology, Applied Chemistry, 3-14-1 Hiyoshi, Kohoku-ku, 223-8522, Yokohama, JAPAN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komaba</LastName><ForeName>Sumika</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Keio University Faculty of Science and Technology Graduate School of Science and Technology, Applied Chemistry, 3-14-1 Hiyoshi, Kohoku-ku, 223-8522, Yokohama, JAPAN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kosono</LastName><ForeName>Shuhei</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Keio University Faculty of Science and Technology Graduate School of Science and Technology, Applied Chemistry, 3-14-1 Hiyoshi, Kohoku-ku, 223-8522, Yokohama, JAPAN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aswathy</LastName><ForeName>Maniyamma</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Keio University Faculty of Science and Technology Graduate School of Science and Technology: Keio Gijuku Daigaku Rikogakubu Daigakuin Rikogaku Kenkyuka, Appled Chemistry, 3-14-1 Hiyoshi, Kohoku-ku, 223-8522, Yokohama, JAPAN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anzai</LastName><ForeName>Itsuki</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Osaka University Research Institute for Microbial Diseases, Molecular Virology, 3-1 Yamadaoka, 565-0871, Suita, JAPAN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Watanabe</LastName><ForeName>Tokiko</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Osaka University Research Institute for Microbial Diseases, Molecular Virology, 3-1 Yamadaoka, 565-0871, Suita, JAPAN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Toshima</LastName><ForeName>Kazunobu</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Keio University Faculty of Science and Technology Graduate School of Science and Technology, Applied Chemistry, 3-14-1 Hiyoshi, Kohoku-ku, 223-8522, Yokohama, JAPAN.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Takahashi</LastName><ForeName>Daisuke</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Keio University Faculty of Science and Technology Graduate School of Science and Technology: Keio Gijuku Daigaku Rikogakubu Daigakuin Rikogaku Kenkyuka, Applied Chemistry, 3-14-1 Hiyoshi, Kohoku-ku, 223-8522, Yokohama, JAPAN.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>07</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Angew Chem Int Ed Engl</MedlineTA><NlmUniqueID>0370543</NlmUniqueID><ISSNLinking>1433-7851</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">antivirals</Keyword><Keyword MajorTopicYN="N">fucoidan</Keyword><Keyword MajorTopicYN="N">heparanase</Keyword><Keyword MajorTopicYN="N">spike protein</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>16</Hour><Minute>23</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>7</Day><Hour>8</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39373347</ArticleId><ArticleId IdType="doi">10.1002/anie.202411760</ArticleId></ArticleIdList></PubmedData></PubmedArticle>